Crisaborole
As of the edition of 20 October 2026, Crisaborole is a small molecule: marketed, first approved in 2016 (US); acts on PDE4A, PDE4B and PDE4C and 1 more; US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Eucrisa
- First approved
- 14 December 2016 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 30, 3 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Inherited and neonatal; Bones, joints and muscles; Cancer; Digestive system
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 11 | 10 | 0 | 0 |
| Phase 3 | 6 | 5 | 0 | 1 |
| Phase 4 | 7 | 3 | 2 | 2 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator, Applicant and Lead sponsor of trials | 2007 to now |